Sign in
CompletedPhase 2

Prazosin for Alcohol Use Disorder With Withdrawal Symptoms

Key facts

Who runs it
Yale University
Where
New Haven, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
152 people enrolled
Started
1 Jul 2021
Ended
30 Jun 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Prazosin
  • 12-Step Facilitation with Relapse Prevention and Contingency Management
Record updated
30 September 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Alcohol Withdrawal (AW) scores of 3 or more on the CIWA-Ar at treatment entry OR 2 or more Alcohol Withdrawal Syndrome (AWS) symptoms and regular weekly heavy drinking at treatment entry
  • Must meet current DSM-5 criteria for moderate to severe Alcohol Use Disorder (AUD) using SCID-I for DSM-5
  • No health conditions that would impact trial participation as verified by screening and physical examination
  • Able to read English and complete study evaluations
  • Able to provide informed written and verbal consent

Who cannot take part

  • Regular use of anticonvulsants, sedatives/hypnotics, oral prescription analgesics (other than non-steroidal anti-inflammatory drugs), antiretroviral medications, tricyclic antidepressants, topiramate, baclofen, and regular weekly use of benzodiazepines, as defined by use of three or more times per week
  • Meet current criteria for moderate to severe substance use disorders from use of any another psychoactive substance, excluding nicotine, cocaine and cannabis
  • Significant underlying medical conditions such as cerebral, renal, thyroid or cardiac pathology which in the opinion of study physician would preclude patient from fully cooperating or be of potential harm during the course of the study
  • Any psychotic disorder or current Axis I psychiatric disorders requiring specific attention, including need for psychiatric medications
  • Prescribed use of antihypertensive medications that duplicate the mechanism of action at the alpha1 receptor as prazosin or are contraindicated, such as those medications that are also alpha1-adrenergic antagonists (i.e., doxazosin, tamsulosin, terazosin) or are beta-blockers (e.g., propranolol); Potential participants who are prescribed cardiovascular/antihypertensive medications will undergo clinical review by the study PIs and team. Individuals who are prescribed anti-hypertensives that do not duplicate the action of prazosin and are not contraindicated, including ACE inhibitors, angiotensin receptor blockers (ARBs), diuretics, and calcium channel blockers, may be allowed to participate after review from the study physician and principal investigators, with careful monitoring of these individuals' blood pressure at all in-person appointments
  • Current use of illicit /non-prescribed opioids more than 2X/month
  • Psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal, current mania)
  • Hypotensive individuals with sitting blood pressure below 100/50 mmHG
  • Women who are pregnant, nursing or refuse to use a reliable form of birth control (as assessed by pregnancy tests during initial medical evaluation, and assessed every two weeks during the course of the study)

Where in United States

  • The Yale Stress Center: Yale UniversityNew Haven, United States

About the trial

What the trial wants to find out

This is a Phase 2 single site randomized clinical trial (RCT) to be supported by a new NIH-NIAAA grant, R01-AA029113-01, to assess the efficacy of Prazosin (16mg/day) versus Placebo over a 12 week treatment period, followed by a 1- and 3- month assessments post-treatment for individuals with Alcohol Use Disorder (AUD) and history of past or current evidence of alcohol withdrawal symptoms. If medical detoxification is required for any patient, patients would be enrolled after medical detoxification. for those not requiring detoxification, they will be enrolled directly without any requirement of alcohol abstinence. All patients will be provided behavioral counseling weekly with a trained counselor to support recovery during the trial. Primary outcome will be percent of any heavy drinking days and secondary drinking outcomes will be percent of subjects with no heavy drinking days (PSNHDD), avg drinks per drinking day and %of any drinking drinking days as well as additional secondary outcomes of craving, mood and anxiety problems.

The 2 groups in the trial

  • Active DrugTreatment being tested

    Prazosin (16mg/day) versus Placebo comparator, administered in t.i.d schedule, in capsules, over a 12 week period, with 2 weeks titration in weeks 1-2 and a 5-day taper in week 12.

    Treatment: Prazosin and 12-Step Facilitation with Relapse Prevention and Contingency Management

  • Placebo DrugPlacebo, for comparison

    Placebo for 12 weeks.

    Treatment: 12-Step Facilitation with Relapse Prevention and Contingency Management

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prazosin Treatment for Alcohol Use Disorder With Alcohol Withdrawal Symptoms
Record updated
30 September 2026